Eleva

What Eleva does

Eleva (legal name: eleva GmbH, operating as Eleva Biologics) is a privately held, clinical-stage biopharmaceutical company headquartered in Freiburg im Breisgau, Germany, that develops complex therapeutic proteins using its proprietary Bryotechnology platform. The platform is built on a novel moss (Physcomitrium patens) expression system, a phototrophic suspension cell culture process that fits standard fermenter equipment and produces biologics with human-like glycosylation patterns that cannot easily be made at scale with conventional CHO or yeast systems. GMP production capacity stands at up to 2,000 liters in-house, tripled to roughly 6,000 liters combined following the February 2025 strategic alliance with 3PBIOVIAN.

The company's clinical pipeline comprises two candidates: CPV-104, a recombinant human complement Factor H currently in Phase 1b for C3 Glomerulopathy (with EU Orphan Drug Designation granted in July 2024) and in late preclinical development as an intravitreal therapy for dry age-related macular degeneration; and aGal/RPV-001, a recombinant alpha-galactosidase enzyme replacement therapy for Fabry disease that has completed a positive Phase 1b trial showing a 78% reduction in sphingolipid levels sustained over 28 days after a single injection.

Eleva operates a dual business model: it advances proprietary therapeutic candidates through clinical development toward future product sales, and concurrently monetizes its moss-based expression platform through non-exclusive licensing, co-development alliances, and contract manufacturing services for pharmaceutical and CDMO partners. The company has raised approximately $74 million in equity financing (led by Zukunftsfonds Heilbronn in January 2021) and has scaled its executive bench in 2025-2026 with new CFO (Donato Spota), CMO (Martin Bauer), and CBO (Erich Rajkovic) appointments to support pipeline progression and business development. With roughly 60 employees, no commercial revenue, and assets still in early clinical stages, Eleva is positioned as a platform-and-pipeline biotech whose near-term value drivers are clinical readouts and partnered platform economics.

Name

Eleva

Legal name

eleva GmbH

Website

https://elevabiologics.com

Company type

Private

Founded year

2009

Operating status

Operating

Headcount range

51–100 employees

Short description

Eleva is a clinical-stage biopharmaceutical company developing novel biologics via its proprietary moss-based expression platform (Bryotechnology). It advances proprietary candidates (CPV-104 for complement disorders, aGal/RPV-001 for Fabry disease) while licensing the platform to pharma and CDMO partners.

Ownership category

akta.pro rank

Product category

Biopharmaceuticals

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Analytical Laboratory Instrument Manufacturing (334516)

SIC

Laboratory Analytical Instruments (3826), Services-Testing Laboratories (8734)

akta.pro primary industry

Therapeutic Enzymes & Enzyme Replacement Therapies (ERT) (HLAAAAAK)

Keywords

• Biopharmaceutical development
• Recombinant protein therapeutics
• Moss-based bioproduction
• Complement disorder therapy
• Enzyme replacement therapy

Headquarters

HQ city

Freiburg

HQ country

Germany

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales

Revenue model

1. Proprietary Drug Development: Eleva develops proprietary therapeutic candidates through clinical stages and commercializes them. Current programs include CPV-104 (Factor H for C3G/dry AMD) and aGal/RPV-001 (for Fabry disease). Revenue would come from product sales upon regulatory approval.
2. Technology Platform Licensing: Licensing agreements for access to proprietary moss-based expression system to pharmaceutical companies and CDMOs for development and manufacturing of complex biologics. Non-exclusive license granted to 3PBIOVIAN.
3. Contract Manufacturing Services: GMP manufacturing services for clinical-grade material using moss-based platform. Partnership with 3PBIOVIAN triples production capacity for current and future development programs.
4. Strategic Partnerships and Co-development: Collaborative development arrangements with partners for new programs using Eleva's platform. Joint development, shared costs, and shared rewards for advancing novel biologics.

Go-to-market motion3 records

Distribution channels4 records

Marketing channels7 records

Core offering

Eleva is a clinical-stage biopharmaceutical company that develops and manufactures novel biologic therapeutics using its proprietary moss-based expression platform (Bryotechnology). The company is advancing two clinical-stage product candidates—recombinant human complement Factor H (CPV-104) for C3 Glomerulopathy and dry AMD, and recombinant alpha-galactosidase (aGal/RPV-001) for Fabry disease—and licenses its moss-based manufacturing platform to pharmaceutical companies and CDMOs.

Product overview

Eleva is a clinical-stage biopharmaceutical company developing novel biologics based on its proprietary moss-based expression platform. The company has two clinical-stage product candidates: Factor H (CPV-104), a recombinant human complement Factor H in Phase 1b development for C3 Glomerulopathy and dry AMD, and aGal (RPV-001), a recombinant alpha-galactosidase enzyme that completed Phase 1b for Fabry disease. Both products are produced using Eleva's transformative moss-based technology platform, which enables manufacturing of complex proteins that are difficult or impossible to produce with conventional expression systems.

Differentiator

Problem solved

Functional benefit

Products and services

• Factor H (CPV-104) Recombinant human complement Factor H developed using Eleva's proprietary moss-based expression platform for complement-mediated kidney diseases, with C3 Glomerulopathy (C3G) as the lead indication and dry age-related macular degeneration (dry AMD) as a second indication via intravitreal formulation.
• aGal (RPV-001) Recombinant alpha-galactosidase A enzyme produced in moss for enzyme replacement therapy in Fabry disease, with glycosylation optimized to enable faster cell uptake via the mannose receptor and more directed organ targeting than mammalian cell-based products.
• Moss-Based Expression Platform (Bryotechnology) Proprietary plant-based cell line derived from Bryophyta (moss) that enables production of complex therapeutic proteins with human-like glycosylation patterns, using a GMP-compliant suspension phototrophic cell culture process suited for standard fermenter equipment with production capacity up to 2,000 liters. Offered to pharmaceutical companies and CDMOs through licensing and co-development partnerships.

Quantifiable outcome

• Normalization of serum C3 levels within 24 hours after Factor H injection in animal models
• +4 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Three partnerships are on record, tiered core and minor.

• 3PBIOVIANcoreStrategic or Co-development Partner · 4 February 2025Strategic GMP manufacturing and technology alliance. 3PBIOVIAN provides production capacity for clinical-grade material for Eleva's pipeline programs including Factor H (CPV-104). 3PBIOVIAN receives non-exclusive license to Eleva's moss-based expression system to build manufacturing capacity for future partnered projects. The alliance triples Eleva's GMP production capacity to approximately 6,000 liters combined.
• University of CologneminorStrategic or Co-development PartnerResearch collaboration on dry AMD preclinical study published in Journal of Neuroinflammation. Evaluated effects of intravitreal Factor H injections on retinal degradation and inflammatory processes.
• 3PBIOVIANcoreTechnology or IntegrationBoth parties will promote Eleva's moss-based technology platform as a novel solution for development of complex biologics and collaborate on programs with future partners and clients.

Scale indicators5 records

Recent moves7 records

Expansion highlights6 records

Regional players

• Chiesi Farmaceutici: Chiesi developed and markets an enzyme replacement therapy for Fabry disease (alfagalactosidase), competing directly with Eleva's aGal. Chiesi is a privately-held European biopharma focused on rare diseases.

Direct peers

• Amicus Therapeutics: Amicus markets Galafold (migalastat) for Fabry disease, directly competing with Eleva's aGal/RPV-001 in the same indication with the same target patient population. Both companies develop treatments for rare diseases with significant unmet need.
• Apellis Pharmaceuticals: Apellis is developing complement therapeutics (Empaveli/Syfovre for PNH and geographic atrophy) and is actively pursuing C3G indications, directly competing with Eleva's CPV-104 in the complement-mediated disease space with overlapping mechanisms of action.
• BioMarin Pharmaceutical: BioMarin has historically competed in Fabry disease and develops enzyme replacement therapies for rare diseases, sharing Eleva's focus on ERTs and rare/orphan indications with similar target patient populations and clinical development pathways.
• Hansa Biopharma: Hansa Biopharma is a Swedish clinical-stage biopharma developing immunomodulatory enzyme-based therapies (imlifidase) for rare diseases, sharing Eleva's profile as a Nordic/European clinical-stage biopharma with novel enzyme-based therapeutics. Eleva's CFO Donato Spota was previously Hansa's CFO.

Broad incumbents

• Sanofi (Genzyme): Sanofi/Genzyme markets Fabrazyme, the dominant enzyme replacement therapy in Fabry disease, directly competing with Eleva's aGal. As a global biopharma incumbent, Sanofi has substantially greater commercial infrastructure and resources than Eleva.
• Alexion (AstraZeneca Rare Disease): Alexion leads the complement therapeutics market with Soliris/Ultomiris (C5 inhibitors) and is developing next-generation complement modulators, competing with Eleva's CPV-104 Factor H approach in complement-mediated diseases including C3G.
• BioCryst Pharmaceuticals: BioCryst is a commercial-stage rare disease biopharma (BCX7353/Orladeyo for HAE) with a similar late-stage clinical development focus on rare diseases and complement-related pathways, comparable in therapeutic area focus though larger in commercial scale than Eleva.

Emerging players

• Omeros Corporation: Omeros is developing complement-targeted therapies (narsoplimab targeting MASP-2) for IgA nephropathy and other complement-mediated renal diseases, partially overlapping with Eleva's CPV-104 in C3G and complement-disorder indications.
• iBio: iBio develops plant-based biomanufacturing technologies (using Nicotiana benthamiana) for therapeutic proteins, sharing Eleva's plant-based expression platform approach and addressing similar challenges in producing complex biologics outside CHO/yeast systems.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/elevabiologics

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles24 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Eleva